ClinicalTrials.gg

Multiple System Atrophy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 207 studies for Multiple System Atrophy across more than 10 countries. 73 are recruiting or about to start. 89 of them are mainly about Multiple System Atrophy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its narrower condition Shy-Drager Syndrome too: 230 studies, 83 open.

Status

Completed
89
Recruiting
57
Active, not recruiting
16
Terminated
14
Status unknown
11
Not yet recruiting
7

Phase

Phase 2
35
Phase 1
27
Phase 3
15
Early Phase 1
11
Phase 4
3

Where

United States
90
France
32
China
26
Italy
21
United Kingdom
19
Germany
13

Who develops what

Add Multiple System Atrophy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 11 programs from 11 companies, 10 with this as their studies’ main aim; 2 with a live phase 3 study; 3 primary completions in the next 12 months. Compare H. Lundbeck, MODAG and Ono Pharmaceutical here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
amlenetug☆ Track1 live phase-3 study: NCT06706622H. Lundbeck A/S
ONO-2808☆ Track1 live phase-3 study: NCT07825402Ono Pharmaceutical Co. Ltd

The 2 in phase 3 with the nearest primary completion, of 11 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (3)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 1 Apr 2027 est.Foralumab Nasal · Tiziana Life Sciences LTD · Phase 2 main aimNCT06868628 A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA) — primary endpoint: Change from Screening to Month 6 in the total MDS-UMSARS score · 5 enrolled
  • 30 Jun 2027 est.YA-101 · Dasher Neuroscience Inc. · Phase 2 main aimNCT06848231 A Phase 2 Study of YA-101 in Patients With Multiple System Atrophy — primary endpoint: Incidence and severity of Adverse Events (AEs) · 75 enrolled
  • 15 Sept 2027 est.emrusolmin · Teva Pharmaceutical Industries, Ltd. · Phase 2 main aimNCT06568237 A Trial to Test if TEV-56286 is Effective for Treatment of Participants With Multiple System Atrophy — primary endpoint: For non-EU: Change From Baseline in the Modified Unified Multiple System Atrophy Rating Scale (UMSARS) Part I Score (excluding item 11) · 349 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Multiple System Atrophy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Coming up

36studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger. 7 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 18 (32%) take healthy volunteers.

Recruiting studies that take each age, of 57
AgeWomenMen
106 (11%)6 (11%)
1823 (40%)23 (40%)
3039 (68%)39 (68%)
4049 (86%)49 (86%)
5057 (100%)57 (100%)
6556 (98%)56 (98%)
7553 (93%)53 (93%)
8531 (54%)31 (54%)

Across all 207 studies, recruiting or not: 19% stop at 75 or younger and 2% at 65; 10% take children; 0% are for women only and 0% for men only; 29% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Multiple System Atrophy studies take

Of 25 phase 1 interventional studies under Multiple System Atrophy, half reached primary completion within 28 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 128 mo20–55 · 25 studies——
Phase 223 mo16–32 · 19 studies——
Interventional, no phase38 mo24–71 · 43 studies—38 mo24–71 · 42 studies
Observational94 mo37–… · 39 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 207. Browse all 207 → or search them.